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Abstract
Background
The overall burden of chronic disease, inflammation and cardiovascular risk increases with
age. Whether the relationship between age and inflammation is impacted by presence of an
adverse metabolic burden is not known.
Methods
We determined inflammatory markers in humans (336 Caucasians and 224 African Ameri-
cans) and in mice, representing a spectrum of age, weight and metabolic burden.
Results
In humans, levels of inflammatory markers increased significantly with age in subjects with-
out the metabolic syndrome, (P=0.009 and P=0.037 for C-reactive protein, P<0.001 and
P=0.001 for fibrinogen, P<0.001 and P=0.005 for serum amyloid-A, for Caucasians and Afri-
can Americans, respectively). In contrast, trend patterns of inflammatory markers did not
change significantly with age in subjects with metabolic syndrome in either ethnic group, ex-
cept for fibrinogen in Caucasians. A composite z-score for systemic inflammation increased
significantly with age in subjects without metabolic syndrome (P=0.004 and P<0.006 for
Caucasians and African Americans, respectively) but not in subjects with metabolic syn-
drome (P=0.009 for difference in age trend betweenmetabolic syndrome and non-metabolic
syndrome). In contrast, no similar age trend was found in vascular inflammation. The findings
in humans were paralleled by results in mice as serum amyloid-A levels increased across
age (range 2-15 months, P<0.01) and were higher in ob/ob mice compared to control mice
(P<0.001).
Conclusions
Presence of a metabolic challenge in mice and humans influences levels of inflammatory
markers over a wide age range. Our results underscore that already at a young age,
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presence of a metabolic burden enhances inflammation to a level that appears to be similar
to that of decades older people without metabolic syndrome.
Introduction
Inflammation is considered as a critical factor for the development of cardiovascular disease
(CVD)[1]. The atherosclerotic process is hallmarked by the infiltration of macrophages and T
cells at the sites of lipid deposition causing the release of cytokines and other bioactive mole-
cules that lead to further infiltration of immune cells. Together, this inflammatory process per-
petuates the formation of a fibrous cap composed mostly of collagen boarded by infiltrating
immune cells that ultimately allows for plaque growth and ischemia [2]. Therefore, the devel-
opment of atherosclerotic lesions in the vascular wall is the net result of many complex pro-
cesses where multiple proinflammatory risk factors contribute by influencing individual
pathophysiological steps [3].
The predictive role of systemic inflammatory markers in CVD is well established, and we
and others have demonstrated that vascular inflammation is also associated with CVD risk
[4]. However, there is a paucity of data indicating to what extent the inflammatory process is
accelerated by the presence of a disadvantageous metabolic setting, such as for example the
presence of metabolic syndrome (MetS) [5]. Many of the components of MetS, such as hyper-
triglyceridemia, low high density lipoprotein (HDL) cholesterol levels, hypertension, abdom-
inal obesity, and increased fasting glucose levels are present early in life resulting in a lifelong
exposure. Much attention has been concentrated on the lifelong relationship between MetS
components and the immune system with current research indicating both as the develop-
mental origins of chronic disease [6]. With an increasing sedentary lifestyle and increasingly
high rates of obesity, exceeding 30% in the US population for most age and gender groups
[7], such conditions are common and the age-adjusted prevalence of MetS is presently
34% [8].
Although traditional cardiovascular risk factors are useful for predicting cardiovascular
events in younger populations, their predictive value decreases with age [9]. Therefore, one
could speculate that presence of an additional inflammatory component, such as MetS, may
play a more substantial role in the pathogenesis of CVD in older compared to younger individ-
uals. However, to what extent an inflammatory contribution to CVD development might be
modulated by age in the absence or presence of a metabolic burden is not known. To test the
relationship between metabolic burden, age, and inflammation and whether a similar pattern is
seen across species, we undertook studies in both humans and mice. We hypothesized that the
degree of an age-associated increase in inflammatory markers would depend on the absence or
presence of a metabolic burden, and that this would be present in both humans and mice. Data
obtained through this study has the potential to inform an understanding of CVD risk
throughout the process of aging and to build a foundation to develop strategies for early
risk intervention.
Materials and Methods
Human Subjects
Subjects were recruited from a patient population scheduled for diagnostic coronary arteriog-
raphy either at Harlem Hospital Center in New York City or at the Mary Imogene Bassett Hos-
pital in Cooperstown, NY. The study design including exclusion and inclusion criteria has
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been described previously [10,11]. Briefly, a total of 648 patients, self-identified as Caucasians
(n = 344), African American (n = 232) or Other (n = 72) were enrolled. Exclusion criteria for
this study included the use of lipid-lowering drugs, as well as hormone replacement therapies.
The present report is based on findings in 560 subjects (336 Caucasians, 224 African Ameri-
cans); 16 subjects were excluded due to incomplete data. The study was approved by the Insti-
tutional Review Boards at Harlem Hospital, the Mary Imogene Bassett Hospital, Columbia
University College of Physicians and Surgeons, and University of California Davis, and in-
formed consent was obtained from all subjects.
Coronary Angiography
The coronary angiograms were read by 2 experienced readers blinded to patient identity, the
clinical diagnosis, and laboratory results. The readers recorded the location and extent of lumi-
nal narrowing for 15 segments of the major coronary arteries [12]. In the present study, pa-
tients were classified as having CAD if a stenosis of50% was found in at least one of the
segments. Patients without CAD were defined as having<50% stenosis in all of the segments.
A composite cardiovascular score (0–75) was calculated based on determination of presence of
stenosis on a scale of 0–5 of the 15 predetermined coronary artery segments.
Human Clinical and Biochemical Assessment
Blood pressure was measured with a random-zero mercury sphygmomanometer. Waist circum-
ference was calculated as the average of 2 measurements taken after inspiration and expiration
at the midpoint between the lowest rib and iliac crest. Participants were asked to fast for 12
hours, and blood samples were drawn approximately 2 to 4 hours before the catheterization
procedure. Serum and plasma samples were separated and stored at -80°C prior to analysis.
Concentrations of total and HDL cholesterol and glucose (Roche, Sommerville, NJ) were deter-
mined using standard enzymatic procedures [13,14]. HDL cholesterol levels were measured
after precipitation of apoB-containing lipoproteins with dextran sulfate [15], and LDL cholester-
ol levels were calculated with the formula of Friedewald et al [16]. High-sensitivity C-reactive
protein (CRP) levels were measured using an enzyme-linked immunoabsorbent assay (ELISA),
standardized according to theWorld Health Organization First International Reference Stan-
dard [17,18]; CV 8.9%. Fibrinogen levels were measured by the clot-rate method of Clauss [19];
CV 3.0%. Insulin levels were assessed using a Coat-A-Count RIA kit (DPC Diagnostic Products
Co, Los Angeles, CA). Homeostasis model assessment—insulin resistance (HOMA-IR) was cal-
culated using the updated model available from the Oxford Centre for Endocrinology and Dia-
betes [20]. Pentraxin-3 (PTX-3) was measured by PTX-3 (human) Detection Set from Alexis
Biochemicals (Axxora, LLC); CV 10.2%. Plasma serum amyloid-A (SAA) concentrations were
measured by ELISA using a commercially available kit (Invitrogen, Inc., Carlsbad, CA) [21]; CV
5.4–10.3%. Lipoprotein-associated phospholipase A2 (Lp-PLA2) mass was assayed using a
microplate-based ELISA; CV 4.8–7.2%, and Lp-PLA2 activity was measured with a colorimetric
activity method (diaDexus, Inc., South San Francisco, CA) [22–24]; CV 6.5–7.8%. All biochemi-
cal assessments were made in duplicate.
We defined the MetS using the revised NCEP-ATP III criteria [25] as having three or more
of the following parameters: fasting plasma glucose100 mg/dl, serum triglycerides 150 mg/
dl, serum HDL cholesterol<40 mg/dl for men and<50 mg/dl for women, blood pressure
130/85 mmHg, or undergoing hypertension treatment, or waist circumference of more than
102 cm for men and 88 cm for women.
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Animal Models
Female young (2 months), middle-aged (12 months), and aged (15–18 months) C57BL/6 mice
were purchased from Jackson Laboratory (Bar Harbor, ME). For experiments using middle-age
and aged mice, mice were purchased from Jackson Laboratory between the ages of 6–9 months
and further aged at the University of California Davis’s Sacramento campus. Additionally,
young (2 months) obese mice congenic for the spontaneous leptin mutation (B6.V-Lepob/ob/J)
were also purchased from Jackson Laboratory (Bar Harbor, ME). Mice were housed under spe-
cific pathogen-free conditions, and all mouse studies were conducted with the approval of the
UC Davis Institutional Animal Care and Use Committee.
For studies involving the use of aged ad libitum fed and aged calorie restricted mice, age-
matched mice were purchased through the NIA Aged Colony (Bethesda, MD). Calorie-restricted
cohorts were fed the NIH31-fortified diet. In accordance with the NIA’s Aged Colony guidelines,
the NIA achieves calorie-restriction by first placing the mice at a 10% calorie restriction, initiated
at 14 weeks of age. The restriction is then increased to 25% at 15 weeks of age, and to 40% at 16
weeks of age. The mice are maintained at 40% calorie restriction throughout life thereafter. Age-
matched ad libitum fed aged mice were also purchased through the NIA colony to serve
as controls.
Murine Assessment of SAA Levels
Murine serum levels of SAA were quantified using a mouse SAA ELISA kit according to the
manufacturer’s protocols; CV 2.7–5.6% (Immunology Consultants Laboratory, Portland, OR).
Briefly, serum was obtained through tail bleeds of resting mice. Eight serial dilutions of stan-
dards of known concentration were performed and plated in accordance to manufacturer’s in-
structions. Serum samples were diluted 1:1000 and plated in duplicate into pre-designated
wells. Samples and standards were incubated in pre-coated wells at room temperature for
60 minutes, washed four times with Wash Solution prior to addition of 100 μl of Enzyme-
Antibody Conjugate. The wells were incubated at room temperature for 60 minutes in the dark
and washed four times as described above. 100 μl of TMB substrate solution was then added to
each well, incubated at room temperature for precisely 10 minutes, and the reaction stopped by
addition of 100 μl of Stop Solution. Colorimetric determination of SAA levels was performed
by reading of absorbance of each well at 450 nm on a plate reader (VERSAma turntable plate
reader).
Murine Adiposity Imaging
Magnetic resonance imaging (MRI) images for mouse data were acquired in collaboration with
the Center for Molecular and Genomic Imaging (CMGI) Facility at the University of Califor-
nia, Davis. Mice were imaged using a Bruker BioSpec 70/30 7T (Bruker Biospin, Ettlingen, Ger-
many) horizontal bore system. Animals were anesthetized with 2% isofluorane and maintained
with 1–2% isoflurane throughout imaging with a nose cone fitted for inhalation. Mice were
kept at normal body temperature using circulating warm air. Mice were inserted into the scan-
ner in a head-first prone orientation. Spin-echo T1-weighted images were obtained through
the mouse body (neck-to-base of the tail) using a 72 mm linear volume coil. Scan sequence pa-
rameters were the following: TR 1000 ms, TE 15 ms and 2 averages. The field of view was
7.7 × 3.85 x 2.0 cm, with a matrix size of 256 x 128 x 40. The corresponding voxel size was
0.3 × 0.3 × 0.5 mm. Images were acquired using ParaVision 5.0 software. After acquisition, im-
ages were transferred into Invenon Research Workplace 4.0 software (Siemens Preclinical) al-
lowing fat to be displayed with high intensity (white).
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Statistical Analysis
For the mouse studies, statistical analysis was performed using Prism software (GraphPad Soft-
ware Inc.). Data were expressed as mean ± SE. For analysis of three or more groups, the one-
way ANOVA test was performed with the Bonferroni post-hoc test. Analysis of differences be-
tween two test groups was performed using the Student’s t-test. A minimum of three mice per
group was used for serum assays. For human studies, analysis of data was done with SPSS sta-
tistical analysis software (SPSS Inc, Chicago, IL). Results were expressed as means ± standard
error of the mean (SEM). Levels of CRP, SAA, PTX-3, triglycerides, insulin, HOMA-IR, Lp-
PLA2 mass, Lp-PLA2 activity and the cardiovascular score were logarithmically transformed to
achieve normality for statistical analysis. Proportions were compared between groups using χ2
test or Fisher’s exact test as appropriate. General linear measurement analyses were used for
anthropometric, metabolic and clinical parameters after adjustment for age and sex. Sex-ad-
justed Pearson’s partial correlation coefficients were calculated for age and inflammatory
markers across ethnicities. To construct a composite score of multiple markers, we first calcu-
lated a z-score for each inflammatory marker [z ¼ ðx  xÞ=SD, where x is an individual mark-
er value, x is the mean marker value, and SD is the standard deviation of marker values]. Using
the individual z-scores, we next calculated a composite z-score for systemic inflammation
[i.e., z-score (systemic) = Average (z-CRP, z-fibrinogen, z-SAA)], and for vascular inflamma-
tion [z-score (vascular) = Average (0.5 z-Lp-PLA2 mass, 0.5 z-Lp-PLA2 activity, z-PTX-3)], as
described previously [4]. As we used Lp-PLA2 mass and activity to calculate a composite z-
score for vascular inflammation, these two parameters were given a coefficient of 0.5 in the for-
mula. Multivariate linear regression analysis was performed to explore the independent associ-
ation of age with the composite z-scores adjusted for confounding variables. An interaction
term for age by presence of MetS allowed a formal test of the difference in age trends for MetS
compared to non-MetS patients, and further calculations based on this model addressed the
trend for MetS and the differences at both younger and older ages. Model assumptions of lin-
earity and normality and homoscedasticity of residuals were validated both analytically and
graphically. Two-tailed p values less than 0.05 were considered statistically significant.
Results
Aging and Obesity Result in Increased Circulating Acute-Phase Proteins
in Normal Mice
We and others have previously shown that circulating levels of acute phase proteins are correlat-
ed with increased risk for CVD [1,4,26,27]. We first sought to examine the impact of aging
upon increased circulating levels of acute phase proteins within mice of varying ages. Because of
species differences between human and mice, serum amyloid A (SAA), a major acute phase pro-
tein indicative of inflammatory responses in mice that is analogous to CRP in humans, was mea-
sured among mice representing increasing ages. Young (2 months), middle aged (12 months),
and aged (15–18 months) mice were assessed for SAA levels at a resting state. Accordingly, SAA
levels increased gradually with age from two to 18 months resulting in a significant correlation
between SAA levels and aging (Fig. 1A).
Aside from age, it was observed that aged mice inherently display increased body mass in
comparison to young lean mice, yet weigh less than young obese (ob/ob) mice (Fig. 1B). It is
well documented that aging is associated with changes in body mass composition, hallmarked
by the loss of lean muscle mass and increase in central, visceral, adiposity [28–30]. Therefore,
we questioned if the increased presence of adipose tissue affected circulating levels of inflam-
matory markers with aging, thereby increasing risk for CVD. To determine adiposity and fat
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deposition within mice, we employed the usage of MRI. For comparison to an obesity model,
young (2 months, ob/ob) congenic obese mice (B6.Cg-Lepob/ob) were included and compared
to young age-matched lean and aged (15 months) mice. MRI imaging demonstrated aged mice
to exhibit greater visceral adiposity in comparison to their lean young counterparts, with obese
mice exhibiting the greatest amount of fat deposits (Fig. 1C).
To dissect the role of metabolic dysregulation on increasing SAA levels, we compared
serum levels of resting young lean and young obese mice (ob/ob). Ob/obmice are congenic for
the mutation in the OB gene resulting in loss of leptin hormone and exhibit symptoms of MetS
including visceral obesity, a diabetes-like syndrome of hyperglycemia, elevated plasma insulin,
and increased circulating LDL and VLDL cholesterol levels (http://jaxmice.jax.org/strain/
000632.html#pheno). Age-matched young ob/obmice demonstrated a significant increase in
SAA levels in comparison to their age-matched young lean counterparts (Fig. 1D). This data
demonstrates that increased adiposity may play a role in inducing increased levels of SAA.
To further determine if age alone, in the absence of adiposity, is crucial for the increased
SAA levels observed in Fig. 1A, we measured serum levels within age-matched (18 month old)
aged calorie-restricted (CR) mice in comparison to aged mice following an ad libitum diet
(AL). Notably, when comparing aged AL fed mice with age-matched, CR mice, a lower body
fat content did not result in any significant differences in SAA levels (Fig. 1E). These results in-
dicate that an increased metabolic burden as well as age contributes to the elevation of
inflammatory markers.
Fig 1. Serum SAA levels in C57BL/6 mice of 2, 12, 15, and 18 months of age (A). Total body weights were assessed for young lean, young obese (ob/ob),
and aged mice (B). MRI images demonstrating distribution of fat deposits in young lean, young obese and aged mice (C). Serum SAA levels in young lean
and age-matched young obese (2 months old) (D), and age-matched aged ad libitum-fed and calorie-restricted mice (18 months of age) (E). N = 3–13,
*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
doi:10.1371/journal.pone.0121947.g001
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Human Studies Parallel Observations in Mouse Model
Based upon our data observed in the mouse model, we next sought to examine the relationship
of age and inflammatory markers in the presence of metabolic burden using patient derived
samples. Clinical characteristics of study subjects with and without MetS are shown in Table 1.
As seen in the table, subjects with MetS were slightly older and more obese, had significantly
higher levels blood pressure, as compared to those without MetS. Levels of CRP, fibrinogen,
Lp-PLA2 activity and PTX-3 were higher in subjects with MetS compared to those without
MetS, while Lp-PLA2 mass levels were significantly lower in the former group.
Table 1. Clinical characteristics of study subjects (adjusted for race and sex).
Characteristics Without MetS (n = 219) With MetS (n = 309) P-value
Hypertension (%) 96 (44%) 238 (77%) <0.001
Postmenopausal (%) 46 (21%) 105 (34%) 0.001
Smoking (%) 86 (39%) 88 (28%) 0.009
Alcohol (%) 94 (43%) 105 (34%) 0.036
Anthropometric
Age (yrs) 54.6±0.7 56.5±0.6 0.021
BMI (kg/m2) 26.0±0.4 31.5±0.3 <0.001
Waist circumference (cm) 91.5±1.0 108.0±0.9 <0.001
Systolic blood pressure (mm Hg) 121±1 130±1 <0.001
Diastolic blood pressure (mm Hg) 74±1 77±1 <0.001
Inflammatory markers
Systemic
CRP (mg/l) 2.4 (1.1–5.2) 4.2 (1.9–11.1) 0.036
SAA (mg/l) 25 (10–92) 45 (18–102) NS
Fibrinogen (mg/dl) 333±7 366±6 <0.001
Vascular
Lp-PLA2 mass (ng/ml) 259 (213–323) 249 (209–312) <0.001
Lp-PLA2 activity (nmol/min/ml) 151 (119–181) 163 (137–194) <0.001
PTX-3 (ng/ml) 1.28 (0.72–2.57) 1.42 (0.93–2.25) 0.144
Metabolic
Total cholesterol (mg/dl) 193±3 200±2 0.006
LDL cholesterol (mg/dl) 119±3 127±2 NS
HDL cholesterol (mg/dl) 51±1 39±1 <0.001
Triglyceride (mg/dl) 99 (75–130) 159 (116–216) <0.001
Glucose (mg/dl) 107±4 140±3 <0.001
Insulin (μU/ml) 10.6 (7.2–16.1) 17.2 (11.9–29.7) NS
HOMA-IR 1.4 (0.9–2.1) 2.3 (1.6–4.0) <0.001
ApoA-I (mg/dl) 133±2 120±1 <0.001
ApoB (mg/dl) 125±3 141±2 <0.001
Cardiovascular diseaseComposite cardiovascular score 5.7 (0.0–20.0) 15.7 (4.2–30.0) <0.001
Data are means ± SEM or for non-normally distributed variables as median (interquartile range). General linear measurement analyses were used for
anthropometric, metabolic and clinical parameters after adjustment for age and sex. Values for triglyceride, insulin, CRP, SAA, Lp-PLA2, PTX-3, HOMA-IR
and composite cardiovascular score were logarithmically transformed to normalize the distribution before statistical analyses. CRP indicates C-reactive
protein; SAA, serum amyloid-A; Lp-PLA2, lipoprotein associated phospholipase A2, PTX-3, pentraxin-3; LDL, low density lipoprotein; HDL, high density
lipoprotein; HOMA-IR, Homeostasis model assessment—insulin resistance; ApoA-I, apolipoprotein A-I; ApoB, apolipoprotein B; NS, not significant.
doi:10.1371/journal.pone.0121947.t001
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To explore the relationship between metabolic burden, inflammation, and age we used two
approaches based on body mass index (BMI) or presence of MetS. We first analyzed the corre-
lation of inflammatory markers with age for three different BMI groups, representing normal
weight (BMI25), overweight (BMI 25–29.9) and obese (BMI30) subjects. As see in
Table 2, there was a significant correlation between the three systemic inflammatory markers
and age in the normal weight group, while only fibrinogen was significantly correlated with age
in the overweight and obese subjects. Further, the z-score, representing a combination of the
systemic markers was associated with age only for the normal weight group. In contrast, the
only significant correlation between vascular inflammatory markers and age was seen for
Lp-PLA2 mass among obese subjects. Notably, the z-score for vascular inflammation was not
associated with age in any BMI group.
When using presence or absence of the MetS to illustrate the effects of metabolic burden, we
noted that all three systemic inflammatory markers as well as the z-score for systemic inflam-
mation were robustly associated with age among subjects without the MetS (Table 3). In con-
trast, no correlations with age were observed for vascular inflammatory markers as well as the
z-score for vascular inflammation among subjects without the MetS. In parallel with our find-
ings across BMI groups, only fibrinogen levels and Lp-PLA2 mass were associated with age
among subjects with the MetS. The trend pattern of each individual inflammatory marker with
age is shown in S1 Fig. For the composite z-scores, no correlation was seen for either systemic
or vascular markers with age among subjects with the MetS. As seen in S1 Table, the findings
with regard to systemic inflammatory markers were similar for African Americans and Cauca-
sians without the MetS. For subjects with the MetS, significant associations between fibrinogen
or Lp-PLA2 with age was only seen among Caucasians. Taken together this data shows that sys-
temic, but not vascular inflammatory markers were associated age in subject without MetS.
Multiple regression models, adjusted for race, sex, BMI, LDL-C, HDL-C and triglyceride,
confirmed the relationships between age and the composite z-score for systemic and vascular
inflammation in subjects with and without the MetS (Table 4). Systemic inflammation on aver-
age was 0.3 standard deviation (SD) higher with each decade older in subjects without MetS
(P<0.001). Subjects with MetS at age 30 already had mean systemic inflammation dramatically
higher than age-comparable counterparts without MetS (P = 0.004) and as high as those
Table 2. Pearson’s partial (adjusted for race and sex) correlation coefficients between age and inflammatory markers across BMI groups *.
Inflammatory markers BMI 25 (n = 140) BMI 25–29.9 (n = 191) BMI >30 (n = 218)
r P r P r P
Systemic
CRP (mg/l) 0.262 0.002 0.100 NS 0.101 NS
Fibrinogen (mg/dl) 0.249 0.004 0.330 <0.001 0.215 0.002
SAA (mg/l) 0.317 <0.001 0.088 NS 0.121 NS
Composite z-score, systemic 0.180 0.038 0.144 NS 0.132 NS
Vascular
Lp-PLA2 mass (ng/ml) 0.007 NS 0.111 NS 0.148 0.032
Lp-PLA2 activity (nmol/min/ml) -0.037 NS 0.085 NS 0.030 NS
PTX-3 (ng/ml) -0.048 NS 0.085 NS 0.037 NS
Composite z-score, vascular -0.002 NS 0.041 NS -0.002 NS
Data for CRP, SAA, Lp-PLA2 and PTX-3 were logarithmically transformed to normalize the distribution of marker values before statistical analyses. CRP
indicates C-reactive protein; SAA, serum amyloid-A; Lp-PLA2, lipoprotein associated phospholipase A2, PTX-3, pentraxin-3; NS, not significant.
doi:10.1371/journal.pone.0121947.t002
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counterparts who were three decades older, as illustrated in unadjusted linear regression lines
(Fig. 2A). After adjustment for covariates, subjects with MetS showed only a slight increase in
systemic inflammation with age of 0.011 per year (from Table 4, the slope for MetS (-) plus the
difference in slopes, or 0.030–0.019, P = 0.03), significantly flatter than for non-MetS subjects
(P = 0.009). Indeed, at by age 70, the MetS subjects no longer had significantly greater systemic
inflammation than their age-comparable counterparts without MetS (difference 0.16, P>0.5).
Vascular inflammatory markers showed neither a significant trend with age, nor any difference
in patterns between MetS and non-MetS subjects (Table 4, Fig. 2B). Patterns were similar with-
in both African Americans and Caucasians (Fig. 2C, 2D). Collectively, these results suggest a
Table 3. Pearson’s partial (adjusted for race and sex) correlation coefficients between age and inflammatory markers in subjects with and without
MetS.
Inflammatory markers Without MetS (n = 219) With MetS (n = 309)
r P r P
Systemic
CRP (mg/l) 0.226 0.001 0.035 NS
Fibrinogen (mg/dl) 0.330 <0.001 0.201 0.001
SAA (mg/l) 0.333 <0.001 -0.016 NS
Composite z-score, systemic 0.232 0.001 0.022 NS
Vascular
Lp-PLA2 mass (ng/ml) 0.031 NS 0.161 0.006
Lp-PLA2 activity (nmol/min/ml) 0.038 NS 0.021 NS
PTX-3 (ng/ml) 0.017 NS 0.110 NS
Composite z-score, vascular 0.028 NS 0.006 NS
Data for CRP, SAA, Lp-PLA2 and PTX-3 were logarithmically transformed to normalize the distribution of marker values before statistical analyses. CRP
indicates C-reactive protein; SAA, serum amyloid-A; Lp-PLA2, lipoprotein associated phospholipase A2, PTX-3, pentraxin-3; NS, not significant.
doi:10.1371/journal.pone.0121947.t003
Table 4. Multiple regression analysis of systemic and vascular z-scores with age, MetS and other cardiovascular risk factors in Caucasians and
African Americans adjusted for confounders *.
Model Independent variables R2 F β P
Model 1
(systemic) 0.169 11.4 <0.001
Age_30 0.030 <0.001
MetS 0.602 0.004
Age_30 × MetS -0.019 0.009
Model 2
(vascular) 0.191 13.1 <0.001
Age_30 0.004 NS
MetS -0.092 NS
Age_30 × MetS 0.002 NS
* Adjusted for race, sex, BMI, LDL cholesterol, HDL cholesterol and triglycerides.
A young healthy reference person for regression estimate was defined as age 30, non-MetS, Caucasian, male. All parameter estimates are estimated the
differences from outcome from reference person. Age_30 refers to trends with age compared to 30 years old person. Interactions with age estimate how
the MetS modifies the trend with age.
doi:10.1371/journal.pone.0121947.t004
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different relationship between age and systemic inflammation depending on the absence or
presence of a metabolic burden irrespective of Caucasian/African American ethnicity.
Discussion
Metabolic factors are important predictors of CVD [31]. It is well recognized that a cluster of
metabolic abnormalities, defined as MetS including hypertriglyceridemia, low HDL-cholester-
ol, hypertension, abdominal obesity, and increased fasting glucose levels, has been associated
with subsequent development of diabetes mellitus and CVD [31–33]. Presently, according to
the NCEP-ATP III definition, roughly one third of middle-aged men and women in the US
have MetS, and the frequency increases to above 50% among the elderly [34]. As age is an im-
portant CVD risk factor, there is a need to better understand mechanisms underlying the con-
tribution of aging to CVD development.
Increasing studies have indicated that metabolic factors are affected by immunological pro-
inflammatory responses. The aging immune microenvironment is characterized as engaging in
a systemic, low-grade, chronic inflammatory state that has been termed “inflammaging”
[35,36], hallmarked by increased cytokine production, such as IL-6 and TNF-α. Both of these
factors induce production of acute phase proteins, including CRP that has become increasingly
correlated with cardiovascular risk [37,38]. Moreover, even with healthy aging, a gradual loss
of lean body mass results in an overall redistribution of total body mass through increases in
Fig 2. Relationship between age and composite z-score of systemic (A) or vascular (B) inflammation in all
subjects by MetS status.Dashed line represents subjects with MetS, whereas straight line represents
subjects without MetS. Relationship between age and composite z-score of systemic inflammation in
Caucasians (C) and African-Americans (D) by MetS status. Lines represent unadjusted linear regression
slopes. Dashed line represents subjects with MetS, whereas straight line represents subjects without MetS.
doi:10.1371/journal.pone.0121947.g002
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lipid deposition [39]. Similar to the aging process, obesity has been shown to have an immuno-
modulatory effect, where cross-talk between adipocytes, non-adipose cells, and immune cells is
thought to lead towards the development and perpetuation of a “meta-inflammatory” state, de-
fined as a state of chronic low-grade systemic inflammation, currently hypothesized to be re-
sponsible for metabolic diseases.
Therefore, in the present study we addressed the issue to what extent an age-associated in-
crease in systemic inflammatory markers would differ depending on the presence of metabolic
burden. To test the generalizability of these results, we conducted studies in both humans and
mice, in both cases representing a spectrum of age ranges and metabolic conditions. The cen-
tral novel finding in our study was that the distribution pattern of inflammatory markers over
age differed with the presence or absence of a metabolic burden. Our mouse studies confirmed
the increase in inflammatory markers, namely acute phase proteins, with age. Yet, we also dem-
onstrated that young (2 month) obese mice with metabolic burden indicated SAA levels that
were comparable to their middle-aged (12 month) counterparts. When examining the effects
of increased metabolic burden in aged mice, calorie-restriction did not affect SAA levels. In
agreement with our mouse studies, human studies demonstrated that levels of inflammatory
markers increased significantly with age in subjects without MetS but much less in subjects
with MetS, which already reach high levels at an earlier age. The results were similar in our
mouse models, representing animals of different ages and weights. Collectively, our results un-
derscore the important influence of a metabolic burden as a modulator for age-related inflam-
matory response. As our results implicate the presence of an enhanced inflammatory burden
already at a younger age in the presence of a metabolic challenge, the findings strengthen the
importance of early interventions to reduce conditions favoring CVD development.
A negative metabolic burden present in early life has been suggested to underlie manifesta-
tions of chronic disease throughout the lifespan. Childhood obesity is an example of such a
metabolic event, and has been suggested to contribute to an alarming shift in the childhood
health spectrum from acute to chronic illnesses with long-term negative effects. Furthermore,
the presence of the MetS at younger ages is likely to lead to a lifetime inflammatory burden and
premature risk for chronic disease manifestations. Although the notion that elevated inflam-
matory markers increase the risk of CVD has been increasingly recognized [40], underlying
mechanisms and pathways remain to be elucidated. Further, an increase of inflammatory cyto-
kines can potentially contribute to the progression of many types of chronic and degenerative
diseases beyond atherosclerosis, such as cancer, obesity, diabetes, and congestive heart failure.
Thus, presence of these risk factors and CVD itself may in turn further stimulate the inflamma-
tory process, resulting in a vicious cycle. It has been demonstrated that increases in inflamma-
tory markers with age are due, at least partly, to a progressive increase in the burden of
cardiovascular risk factor and morbidity [41].
As inflammation is an integral and necessary part of the response to pathogens and consti-
tutes an important part of the immune defense system, it is important to have a better under-
standing of the role of individual markers of inflammation in predicting risk of disease
development. We have previously reported an increase in the systemic, but not vascular, in-
flammatory burden with age [4], suggesting a more diversified relationship between inflam-
matory markers and disease. In the present paper, we extended these findings in several
ways. First, we extended our study to the impact of a metabolic burden on the relationship
between inflammation and age. Second, we sought to assess whether this relationship would
be present in an animal model, using mice representing different ages and weight. Our find-
ings in humans and our animal models were similar, implicating that under a metabolic bur-
den, a pro-inflammatory condition was present from an early age, and also that the age-
associated increase in inflammatory markers was considerably less. Furthermore, our results
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suggest that the presence of the MetS has a greater modulatory effect on age-related inflam-
matory response for systemic than vascular inflammatory markers. This may implicate that
vascular inflammation may reflect more specific to a localized atherogenic process but less to
a more widespread inflammatory process.
We acknowledge some of the limitations of this study. In view of the complexity of the in-
flammatory process and the considerable arsenal of markers available, it is well recognized that
a classification of systemic vs. vascular inflammatory markers likely represent a relatively nar-
row and perhaps somewhat simplistic view. However, we nevertheless adopted this approach
as an initial attempt to address the relationship of individual inflammatory markers with other
cardiovascular risk factors. Furthermore, the cross-sectional study design does not allow us to
evaluate the causative and longitudinal effect of age and other factors that might influence on
levels of inflammatory markers. Subjects in our study were recruited from patients scheduled
for coronary angiography and are likely more typical of a high-risk patient group than the gen-
eral population at large. However, utility of high-risk population is particularly valuable in as-
sessing inflammatory factors that might be enriched in this population and ultimately their
effects on risk of CVD. We did study two race/ethnicity groups but expanded studies are need-
ed to investigate other ethnic background groups. Although our findings support the notion
that systemic inflammatory burden measured as increased levels of inflammatory markers is
persistently elevated by age, additional studies are warranted to verify these results in more
general populations as well as in prospective studies over the lifespan.
In conclusions, the findings suggest that an increase of inflammatory burden over age dif-
fered in subjects with or without a metabolic challenge. Our results underscore the important
influence of an unfavorable metabolic status as a modulator for age-related inflammatory re-
sponse with an enhanced inflammatory burden already at a younger age. The results also em-
phasize the importance of a better understanding of specific inflammatory pathways in
designing preventive measures.
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